ZIOPHARM Oncology Stock Rating Lowered by Zacks (ZIOP)
ZIOPHARM Oncology (NASDAQ:ZIOP) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Wednesday. They currently have a $3.80 price target on the stock. Zacks‘s price target suggests a potential upside of 6.15% from the stock’s previous close.
ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 0.14% during mid-day trading on Wednesday, hitting $3.575. The stock had a trading volume of 300,131 shares. ZIOPHARM Oncology has a 52 week low of $2.30 and a 52 week high of $5.58. The stock’s 50-day moving average is $3.86 and its 200-day moving average is $4.08. The company’s market cap is $358.6 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.10). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. On average, analysts predict that ZIOPHARM Oncology will post $-0.44 earnings per share for the current fiscal year.
ZIOPHARM Oncology, Inc, is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (NASDAQ:ZIOP) for the treatment of cancer.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.